EP0282959A2

EP0282959A2 - Substituted 9-amino-tetrahydro-acridines and related compounds, a process for their preparation and their use as medicaments

Info

Publication number: EP0282959A2
Application number: EP88104042A
Authority: EP
Inventors: Gregory Michael Shutske; Grover Cleveland Helsley
Original assignee: Hoechst Roussel Pharmaceuticals Inc
Current assignee: Aventis Pharmaceuticals Inc
Priority date: 1987-03-17
Filing date: 1988-03-15
Publication date: 1988-09-21
Also published as: AU1314188A; NZ223875A; NO881164L; ZA881865B; IL85741A; DK172864B1; FI881223A0; US5391553A; HU201018B; AU6824090A; AU635370B2; KR880011111A; NO173498B; PT86986A; AU633668B2; DK143588D0; AU608300B2; DK143588A; FI881223A; NO881164D0

Abstract

There are disclosed compounds having the formula wherein n is 1-4; X is alkyl of 3-18 carbon atoms, cycloalkyl of 3-7 carbon atoms or cycloalkylloweralkyl; R is hydrogen, loweralkyl or loweralkylcarbonyl; R₁ is hydrogen, loweralkyl, loweralkylcarbonyl, aryl, diloweralkylaminoloweralkyl, arylloweralkyl, diarylloweralkyl, oxygen-bridged arylloweralkyl or oxygen-bridged diarylloweralkyl; stereo isomers thereof and pharmaceutically acceptable acid addition salts thereof, which are useful for enhancing memory, methods for synthesizing them, and pharmaceutical compositions comprising an effective memory enhancing amount of such a compound.

Description

This invention relates to compounds having the formula
wherein n is 1-4; X is alkyl of 3-18 carbon atoms, cycloalkyl of 3-7 carbon atoms or cycloalkylloweralkyl; R is hydrogen, loweralkyl or loweralkylcarbonyl; R₁ is hydrogen, loweralkyl, loweralkylcarbonyl, aryl, diloweralkylaminoloweralkyl, arylloweralkyl, diarylloweralkyl, oxygen-bridged arylloweralkyl or oxygen-bridged diarylloweralkyl; stereo isomers thereof, and pharmaceutically acceptable acid addition salts thereof, which are useful for enhancing memory, methods for synthesizing them, and pharmaceutical compositions comprising an effective memory enhancing amount of such a compound.
This invention also relates to compounds having the formula
wherein n and X are as defined above, R₂ and R₃ are hydrogen or loweralkyl, and Y is halogen, hydroxy or loweralkoxy, which are useful as intermediate compounds for synthesizing the compounds of Formula I and methods for synthesizing them.
Throughout the specification and the appended claims, a given chemical formula or name shall encompass all stereo, geometrical and optical isomers thereof where such isomers exist, as well as pharmaceutically acceptable acid addition salts thereof and solvates thereof such as for instance hydrates.
The following definitions shall apply throughout the specification and the appended claims.
Unless otherwise stated or indicated, the term alkyl denotes a straight or branched alkyl group having from 3 to 18 carbon atoms. Examples of said alkyl include n-propyl, iso-butyl, heptyl, decyl, dodecyl, hexadecyl and octadecyl.
Unless otherwise stated or indicated, the term loweralkyl denotes a straight or branched alkyl group having from 1 to 6 carbon atoms. Examples of said loweralkyl include methyl, ethyl, n-propyl, iso-butyl, pentyl and hexyl.
Unless otherwise stated or indicated, the term cycloalkyl denotes a saturated ring containing 3 to 7 carbon atoms. Examples of said cycloalkyl include cyclopropyl, cyclohexyl and cycloheptyl.
Unless otherwise stated or indicated, the term halogen shall mean fluorine, chlorine, bromine or iodine.
Unless otherwise stated or indicated, the term aryl shall mean an unsubstituted phenyl group or phenyl group substituted with 1, 2 or 3 substituents each of which being independently loweralkyl, loweralkoxy, halogen, hydroxy, trifluoromethyl, phenoxy or benzyloxy.
Unless otherwise stated or indicated, the term oxygen-bridged shall signify the fact that an oxygen atom is present between aryl and loweralkyl groups and/or an oxygen atom has replaced a methylene group in the loweralkyl group, with the proviso that said methylene group is not alpha to the amino nitrogen carrying the groups R and R₁. Thus, for instance, examples of oxygen-bridged arylloweralkyl include 3-phenoxypropyl and 4-phenoxybutyl, and examples of oxygen-bridged diarylloweralkyl include 2-[bis(4-fluorophenyl)methoxy]ethyl and 2-[bis(3-fluorophenyl)methoxy]ethyl.
The compounds of this invention are prepared by utilizing one or more of the steps described below.
In order to simplify the description of the synthetic schemes, the description will be presented with specific reference to the situation where the group x is cyclohexyl and occupies a specific position in the benzene ring, but it will readily be understood that the synthetic schemes can also be applied to the other situations by making obvious modifications. The substituted anthranilic ester of formula V and its analogues where the group X is other than cyclohexyl, which are used as starting materials, are readily synthesized from the appropriate substituted anilines using conventional techniques well known in the art, such as described by Fuhrer and Gschwend, J. Org. Chem. 44, 1133 (1979) or LaMahieu et al., J. Med. Chem. 26, 420 (1983).
Throughout the description of the synthetic steps, the definitions of n, R and R₁ are as given above unless otherwise stated or indicated.

STEP A

A compound of Formula II can be prepared by reacting compound V, for example, methyl-5-cyclopropyl-2-aminobenzoate, with a cycloalkanone of formula VI. Said reaction can be conducted in a suitable solvent such as benzene, toluene or xylene at a temperature of about 80-150°C in the presence of an acid catalyst such p-toluene sulfonic acid, benzenesulfonic acid or methanesulfonic acid.

STEP B

A compound of Formula III can be prepared in a manner similar to Step A by reacting the compound of formula VII with an alkyl 2-cycloalkanonecarboxylate of formula VIII. Said reaction can be conducted at 20-80°C in the presence of a suitable acid catalyst such as those mentioned above.

STEP C

A compound of Formula IVa can be prepared by reacting compound II with phosphorous pentoxide in the presence of a high boiling tertiary amine such as N,N-dimethylcyclohexylamine. Said reaction can be conducted without additional solvent at a temperature of about 170-220°C.

STEP D

Compound IVa can also be prepared by cyclizing compound IIIa at a temperature of 150-280°C in a solvent such as liquid paraffin or diphenyl ether.

STEP E

A compound of Formula IVb can be prepared by reacting compound IVa with phosphorous oxychloride and phosphorous pentachloride. Said reaction can be conducted at a temperature of about 100-150°C.
The bromine analogue of compound IVb can be prepared in a similar manner, namely, for instance by reacting compound IVa with phosphorus oxybromide and phosphorus pentabromide. The fluorine and iodine analogues of compound IVb can be prepared by replacing the chlorine atom of compound IVb with fluorine or iodine in a routine manner known to the art.

STEP F

A compound of Formula I can be prepared by reacting compound IVb with an amine of formula IX. Said reaction can be conducted at a temperature of 120-220°C in the presence of an acidic catalyst such as ammonium chloride or phenol.
Steps A, C, E and F can be combined into a single step. Thus compound I can be obtained by heating together a mixture of phosphorous pentoxide, N,N-dimethylcyclohexylamine and the hydrochloride of amine X, and thereafter adding compound Va followed by a cycloalkanone of formula VI. Typically, said reaction is carried out at a temperature of 150-250°C.
The compounds of Formula I of the present invention can be used for the treatment of various memory dysfunctions characterized by decreased cholinergic function, such as Alzheimer's disease.
This utility can be ascertained by determining the ability of these compounds to inhibit the activity of the enzyme acetylcholinesterase and thereby increase the acetylcholine levels in the brain.
This utility can also be ascertained by determining the ability of these compounds to restore cholinergically deficient memory in the Dark Avoidance Assay. In this assay mice are tested for their ability to remember an unpleasant stimulus for a period of 24 hours. A mouse is placed in a chamber that contains a dark compartment; a srong incandescent light drives it to the dark compartment, where an electric shock is administered through metal plates on the floor. The animal is removed from the testing apparatus and tested again, 24 hours later, for the ability to remember the electric shock.
If scopolamine, an anticholinergic that is known to cause memory impairment, is administered before an animal's initial exposure to the test chamber, the animal re-enters the dark compartment shortly after being placed in the test chamber 24 hours later. This effect of scopolamine is blocked by an active test compound, resulting in a greater interval before re-entry into the dark compartment.
Effective quantities of the compounds of the invention may be administered to a patient by any of the various methods, for example, orally as in capsules or tablets, parenterally in the form of sterile solutions or suspensions, and in some cases intravenously in the form of sterile solutions. The free base final products, while effective themselves, may be formulated and administered in the form of their pharmaceutically acceptable acid addition salts for purposes of stability, convenience of crystallization, increased solubility and the like.
Acids useful for preparing the pharmaceutically acceptable acid addition salts of the invention include inorganic acids such as hydrochloric, hydrobromic, sulfuric, nitric, phosphoric and perchloric acids, as well as organic acids such as tartaric, citric, acetic, succinic, maleic, fumaric and oxalic acids.
The active compounds of the present invention may be orally administered, for example, with an inert diluent or with an edible carrier, or they may be enclosed in gelatin capsules, or they may be compressed into tablets. For the purpose of oral therapeutic administration, the active compounds of the invention may be incorporated with excipients and used in the form of tablets, troches, capsules, elixirs, suspensions, syrups, wafers, chewing gum and the like. These preparations should contain at least 0.5% of active compound, but may be varied depending upon the particular form and may conveniently be between 4% to about 70% of the weight of the unit. The amount of active compound in such compositions is such that a suitable dosage will be obtained. Preferred compositions and preparations according to the present invention are prepared so that an oral dosage unit form contains between 1.0-300 milligrams of active compound.
The tablets, pills, capsules, troches and the like may also contain the following ingredients: a binder such as micro-crystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, cornstarch and the like; a lubricant such as magnesium stearate or Sterotex; a glidant such as colloidal silicon dioxide; and a sweetening agent such as sucrose or saccharin may be added or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring. When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier such as a fatty oil. Other dosage unit forms may contain other various materials which modify the physical form of the dosage unit, for example, as coatings. Thus tablets or pills may be coated with sugar, shellac, or other enteric coating agents. A syrup may contain, in addition to the active compounds, sucrose as a sweetening agent and certain preservatives, dyes, coloring and flavors. Materials used in preparing these various compositions should be pharmaceutically pure and non-toxic in the amounts used.
For the purpose of parenteral therapeutic administration, the active compounds of the invention may be incorporated into a solution or suspension. These preparations should contain at least 0.1% of active compound, but may be varied between 0.5 and about 30% of the weight thereof. The amount of active compound in such compositions is such that a suitable dosage will be obtained. Preferred compositions and preparations according to the present invention are prepared so that a parenteral dosage unit contains between 0.5 to 100 milligrams of active compound.
The solutions or suspensions may also include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. The parenteral preparations can be enclosed in disposable syringes or multiple dose vials made of glass or plastic.
Examples of the compounds of this invention include:
9-amino-7-cyclopropyl-1,2,3,4-tetrahydroacirdine;
7-cyclopropyl-9-methylamino-1,2,3,4-tetrahydroacridine;
9-benzylamino-7-cyclopropyl-1,2,3,4-tetrahydroacridine;
9-anilino-7-cyclopropyl-1,2,3,4-tetrahydroacridine;
9-amino-7-cyclohexyl-1,2,3,4-tetrahydroacridine;
7-cyclohexyl-9-ethylamino-1,2,3,4-tetrahydroacridine;
9-benzylamino-7-cyclohexyl-1,2,3,4-tetrahydroacridine;
7-cyclohexyl-9-(4-methylanilino)-1,2,3,4-tetrahydroacridine;
9-amino-7-(1,1-dimethylethyl)-1,2,3,4-tetrahydroacridine;
7-(1,1-dimethylethyl)-9-propylamino-1,2,3,4-tetrahydroacridine;
7-(1,1-dimethylethyl)-9-(4-fluorobenzylamino)-1,2,3,4-tetrahydroacridine;
9-(4-chloroanilino)-7-(1,1-dimethylethyl)-1,2,3,4-tetrahydroacridine;
9-amino-7-decyl-1,2,3,4-tetrahydroacridine;
7-decyl-9-methylamino-1,2,3,4-tetrahydroacridine;
7-decyl-9-(4-methoxybenzyl)-1,2,3,4-tetrahydroacridine;
9-anilino-7-decyl-1,2,3,4-tetrahydroacridine;
9-amino-7-cyclopropyl-3,4-dihydro-1H-cyclopenta[b]quinoline;
and
11-amino-2-cyclopropyl-7,8,9,10-tetrahydro-6H-cyclohepta[b]quinoline.
Following examples are presented in order to illustrate this invention.

EXAMPLE 1

7-Cyclohexyl-9-hydroxy-1,2,3,4-tetrahydroacridine

4-Cyclohexylamine (23.15g) and 2-ethoxycarbonylcyclohexanone (25.0g) were stirred in 100 mL of benzene containing 0.20g of p-toluenesulfonic acid monohydrate. After stirring for 4 hours at room temperature the reaction mixture was refluxed for 3 hours with the separation of water. At the end of this time the benzene was evaporated and the residue was dissolved in 150 mL of phenyl ether and the resultant mixture refluxed for 30 minutes. The product which separated upon cooling was filtered off and washed with ether to give 18.22 g of product which was analytically pure without further purification, mp 292-295°C.

EXAMPLE 2

9-Chloro-7-cyclohexyl-1,2,3,4-tetrahydroacridine

7-Cyclohexyl-9-hydroxy-1,2,3,4-tetrahydroacridine (15.539g) was refluxed for 45 minutes in 100 mL of POCl₃. At the end of this time the reaction mixture was concentrated under reduced pressure and the residue was distributed between water and ether. Aqueous ammonia was added portionwise with shaking until all the organic material was dissolved in the ether layer. Evaporation and recrystallization of the residue from methanol gave 14.81g of analytically pure product, mp 89-91°C.

EXAMPLE 3

9-Benzylamino-7-cyclohexyl-1,2,3,4-tetrahydroacridine hydrochloride

9-Chloro-7-cyclohexyl-1,2,3,4-tetrahydroacridine (3.0g) was dissolved in 60 mL of phenol. Benzyl amine (3.21g) was added and the reaction mixture was heated at 150°C. After 3 hours the reaction mixture was poured into 10% NaOH solution and extracted with ether. The organic phase was washed again with 10% NaOH solution and then with water. Treatment of the organic phase with 5% HCl solution gave a hydrochloride salt which was insoluble in both phases. It was filtered off, recrystallized from isopropanol and dried to give 2.70g of analytically pure product, mp 272-274°C.

EXAMPLE 4

7-Dodecyl-9-hydroxy-1,2,3,4-tetrahydroacridine

4-Dodecylaniline (15.7 g) was dissolved in 100 mL of benzene and then 2-ethoxycarbonylcyclohexane (10.2 g) was added, followed by 0.20 g of p-toluenesulfonic acid. The reaction mixture was stirred for three days and then refluxed for 2 hours with the separation of H₂O. The benzene was evaporated from this mixture, which was then dissolved in 100 mL of phenyl ether and refluxed for 45 minutes. At the end of this time the reaction mixture was allowed to cool and the precipitated product was filtered off. This crude product was purified by flash chromatography (20% ethyl acetate/CH₂Cl₂) and then recrystallized from 1,2-dichloroethane/methanol to give 1.31 g, mp 225-226°.

EXAMPLE 5

9-Chloro-7-dodecyl-1,2,3,4-tetrahydroacridine

Three grams of 7-dodecyl-9-hydroxy-1,2,3,4-tetrahydroacridine was refluxed for 30 minutes in 30 mL of POCl₃. At the end of this time the POCl₃ was evaporated and the residue distributed between aqueous NH₃ and ethyl ether. The organic phase was dried and evaported to give 9-chloro-7-dodecyl-1,2,3,4-tetrahydroacridine (3.0 g) as a solid. A small sample was recrystallized from methanol to give fine needles, mp 36-38°.

EXAMPLE 6

9-Benzylamino-7-dodecyl-1,2,3,4-tetrahydroacridine hydrochloride

9-Chloro-7-dodecyl-1,2,3,4-tetrahydroacridine (2.85 g) was heated at 150° in 60 mL of phenol containing 2.46 g of benzylamine. After 3 hours the reaction mixture was distributed between Et₂O and 10% NaOH aqueous solution. The organic phase was washed once more with 10% NaOH, once with H₂O, and then treated with 5% HCl. The insoluble hydrochloride was filtered off and recrystallized from isopropanol to give 2.15 g of analytically pure product, mp 194-195°.

EXAMPLE 7

9-Amino-7-cyclohexyl-1,2,3,4-tetrahydroacridine hydrochloride

Four grams of 9-chloro-7-cyclohexyl-1,2,3,4-tetrahydroacridine was dissolved in 50 ml of phenol and heated to 150° as NH₃ was bubbled into the reaction mixture for 2 hours. At the end of this time, the reaction mixture was distributed between CH₂Cl₂ and 10% NaOH aqueous solution. The organic phase was washed again with 10% NaOH and then with H₂O. Treatment with 5% HCl solution gave an insoluble hydrochloride which was filtered off and recrystallized from H₂O and then from MeOH-Et₂O to give 2.15 g, mp 320-325°(d).

Claims

1. A compound having the formula I

wherein n is an integer of 1 to 4; X is C₃-C₁₈-alkyl, C₃-C₇-cycloalkyl or C₃-C₇-cycloalkyl-C₁-C₆-alkyl; R is hydrogen, C₁-C₆-alkyl or C₁-C₆-alkylcarbonyl; and R₁ is hydrogen, C₁-C₆-alkyl, C₁-C₆-alkylcarbonyl, aryl, diaryl-C₁-C₆-alkyl, di-C₁-C₆-alkylamino-C₁-C₆-alkyl, aryl-C₁-C₆-alkyl, diaryl-C₁-C₆-alkyl, oxygen-bridged aryl-C₁-C₆-alkyl or oxygen-bridged diaryl-C₁-C₆-alkyl; a stereo, optical or geometrical isomer thereof, or a pharmaceutically acceptable acid addition salt thereof.

2. A compound as defined in claim 1 where R is hydrogen and R₁ is hydrogen, C₁-C₆-alkyl or aryl-C₁-C₆-alkyl.

3. A compound as defined in claim 2, where n is 2.

4. A compound as defined in claim 3, where X is cyclohexyl or dodecyl and R₁ is a hydrogen or benzyl.

5. A compound having the formula II

wherein n and X are as defined in claim 1 and R₂ is hydrogen or C₁-C₆-alkyl.

6. A compound as defined in claim 5, where n is 2.

7. A compound having the formula III

wherein n and X are as defined in claim 1 and R₃ is hydrogen or C₁-C₆-alkyl.

8. A compound as defined in claim 7, where n is 2.

9. A compound having the formula IV

wherein n and X are as defined in claim 1 and Y is halogen, hydroxy or C₁-C₆-alkoxy.

10. A compound as defined in claim 8, where n is 2.

11. A pharmaceutical composition which comprises an effective amount of a compound as defined in claim 1 and a carrier therefor.

12. Use of a compound as defined in claim 1 for the preparation of a medicament having the activity of increasing the cholinergic function in mammals.

13. A process for the preparation of a compound of the formula I

wherein n is an integer of 1 to 4; X is C₃-C₁₈-alkyl, C₃-C₇-cycloalkyl or C₃-C₇-cycloalkyl-C₁-C₆-alkyl; R is hydrogen, C₁-C₆-alkyl or C₁-C₆-alkylcarbonyl; and R₁ is hydrogen, C₁-C₆-alkyl, C₁-C₆-alkylcarbonyl, aryl, diaryl-C₁-C₆-alkyl, di-C₁-C₆-alkylamino-C₁-C₆-alkyl, aryl-C₁-C₆-alkyl, diaryl-C₁-C₆-alkyl, oxygen-bridged aryl-C₁-C₆-alkyl or oxygen-bridged diaryl-C₁-C₆-alkyl; a stereo, optical or geometrical isomer thereof, or a pharmaceutically acceptable acid addition salt thereof, which comprises

a) reacting a compound of formula IV

where Y is halogen, and X and n are as defined, with an amine of formula
HNRR₁ (IX)
wherein R and R₁ are as defined, in the presence of an acidic catalyst, or

b) heating together a mixture of phosphorous pentoxide, N,N-dimethylcyclohexylamine and the hydrochloride of an amine of the formula IX
HNRR₁ (IX),
thereafter adding a compound of formula V

followed by a cycloalkanone of formula VI